The Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for Leqembi, a monoclonal antibody treatment shown to slow cognitive decline in people with early Alzheimer ...

Leqembi targets amyloid plaques in the brain. It’s a monoclonal antibody that is delivered through an intravenous (IV) infusion every four weeks. Monoclonal antibodies are man-made proteins that ...

Leqembi is a biologic drug and belongs to a drug class called monoclonal antibodies. Leqembi is not available in a biosimilar version. Keep reading for specific information about the dosage of ...

Medically reviewed by Femi Aremu, PharmD Dementia is a loss of brain function that affects memory, thinking, judgment, ...

Biogen/Eisai’s LEQEMBI (lecanemab) Overview LEQEMBI, developed by Biogen and Eisai, is a humanized IgG1 monoclonal antibody targeting both soluble aggregated forms (protofibrils) and insoluble ...

The first anti-amyloid monoclonal antibody -- and the first drug of any ... anti-amyloid agent gained approval in January 2023: lecanemab (Leqembi). It became the first in the class to move ...

Leqembi is a Aβ monoclonal antibody that preferentially binds to toxic protofibrils (soluble Aβ aggregates), in addition to targeting and reducing Aβ plaques (insoluble Aβ aggregates).

Leqembi is the result of a long-standing ... It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid ...

The prescribing information for Leqembi approved by the FDA includes a warning for amyloid-related imaging abnormalities (ARIA), which are known to occur with antibodies of this class, and the two ...

In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the ...